The effects of lipid-regulating therapy on haemostatic parameters

被引：34

作者：

Milionis, HJ

Elisaf, MS

Mikhailidis, DP

机构：

[1] Royal Free Hosp, Vasc Dis Prevent Clin, Dept Clin Biochem, London NW3 2QG, England

[2] Univ Ioannina, Sch Med, Dept Internal Med, Ioannina, Greece

来源：

CURRENT PHARMACEUTICAL DESIGN | 2003年 / 9卷 / 29期

关键词：

atherothrombosis; coagulation; fibrates; fibrinogen; fibrinolysis; fish oil; rheology; haemostasis; LDL-aphaeresis; lipid lowering drugs; lipoproteins; platelets; statins;

D O I：

10.2174/1381612033453820

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

There is growing evidence that the components of the haemostatic system play a significant role in the development and progression of atherosclerosis and its complications. Lipid-lowering interventions have been associated with a significant reduction of morbidity and mortality. However. the improvement in cardiovascular risk seen in several clinical trials is incompletely explained by cholesterol reduction. Therefore, the benefit from lipid lowering drugs may involve non-lipid mechanisms. These include beneficial effects on the arterial wall, improved endothelial function and a favourable influence on blood rheology and thrombogenesis. In this review, we consider the influence of lipid-lowering interventions on rheological and haemostatic parameters as well as the potential clinical relevance of these effects.

引用

页码：2425 / 2443

页数：19

共 291 条

[51]

Cimminiello C, 1999, EUR HEART J SUPPL, V1, pA8

[52] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[53]

COCCHERI S, 1971, ACTA MED SCAND, P273

[54]

Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy, 1994, BMJ-BRIT MED J, V308, P159, DOI DOI 10.1136/BMJ.308.6922.159

[55] ABOLITION OF INVIVO PLATELET THROMBUS FORMATION IN PRIMATES WITH MONOCLONAL-ANTIBODIES TO THE PLATELET GPIIB-IIIA RECEPTOR - CORRELATION WITH BLEEDING-TIME, PLATELET-AGGREGATION, AND BLOCKADE OF GPIIB-IIIA RECEPTORS [J].